Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

New and superior adrenal imaging agent, /sup 131/I-6. beta. -iodomethyl-19-nor-cholesterol (NP-59): evaluation in humans

Journal Article · · J. Clin. Endocrinol. Metab.; (United States)

We have reported tissue distribution studies in rats and dogs with a new adrenal imaging agent, /sup 131/I-6..beta..-iodomethyl-19-nor-cholesterol (NP-59). This agent concentrated five times higher in the adrenal cortex than /sup 131/I-19-iodocholesterol without increased concentration in non-adrenal tissues. We now report in 34 patients, the findings on scintigraphy with NP-59 compared with angiograms and/or adrenal vein hormone levels and histopathology, including 13 patients with hypercortisolism, 12 with primary aldosteronism, 2 with low renin hypertension, 5 with catecholamine excess, 1 with a liver metastasis from an aldosterone producing adrenal cortical carcinoma, and 1 with anaplastic adrenal cortical carcinoma. NP-59 adrenal cortical uptake was more rapid and intense and background activity was less prominent, allowing earlier and more definite interpretation of images than was possible with /sup 131/I-19-iodocholesterol.

Research Organization:
Univ. of Michigan, Ann Arbor
OSTI ID:
7300349
Journal Information:
J. Clin. Endocrinol. Metab.; (United States), Journal Name: J. Clin. Endocrinol. Metab.; (United States) Vol. 45:2; ISSN JCEMA
Country of Publication:
United States
Language:
English